{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:21:32Z","timestamp":1784636492027,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.canlet.2020.12.031","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T01:56:32Z","timestamp":1609120592000},"page":"147-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"501","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-0522","authenticated-orcid":false,"given":"Su","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.12.031_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-018-0109-6","article-title":"Emerging therapies in advanced hepatocellular carcinoma","volume":"7","author":"Medavaram","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.12.031_bib3","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2020.12.031_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11684-019-0728-2","article-title":"Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check","volume":"14","author":"Lee","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.canlet.2020.12.031_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2016.03.014","article-title":"Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma","volume":"379","author":"Yao","year":"2016","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.12.031_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2020.12.031_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.canlet.2020.12.031_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2020.12.031_bib11","first-page":"e831","article-title":"A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer","volume":"19","author":"Wu","year":"2018","journal-title":"Clin. Lung Canc."},{"key":"10.1016\/j.canlet.2020.12.031_bib12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.canlet.2020.12.031_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant. Rev."},{"key":"10.1016\/j.canlet.2020.12.031_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1188\/13.CJON.425-433","article-title":"Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer","volume":"17","author":"Grenon","year":"2013","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.canlet.2020.12.031_bib15","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"Bhaskaran","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2020.12.031_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer","volume":"7","author":"Azoulay","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.12.031_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324\u2008168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2020.12.031_bib18","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2020.12.031_bib19","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-05-2489","article-title":"Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice","volume":"12","author":"Wysocki","year":"2006","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.12.031_bib20","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/annonc\/mdu178","article-title":"'Pre-cachexia': a non-existing phenomenon in cancer?","volume":"25","author":"Blauwhoff-Buskermolen","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2020.12.031_bib21","doi-asserted-by":"crossref","first-page":"E9635","DOI":"10.1073\/pnas.1703431114","article-title":"Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production","volume":"114","author":"Nakamura","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.12.031_bib22","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-10-2577","article-title":"The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression","volume":"17","author":"Hedley","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.12.031_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2015.09.008","article-title":"Erythropoietin stimulates tumor growth via EphB4","volume":"28","author":"Pradeep","year":"2015","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.12.031_bib24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI10557","article-title":"Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice","volume":"106","author":"Cole","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.12.031_bib25","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1172\/JCI119769","article-title":"Angiotensin II stimulates proliferation of normal early erythroid progenitors","volume":"100","author":"Mrug","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.12.031_bib26","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1038\/s41467-019-12433-w","article-title":"Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes","volume":"10","author":"Zhong","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2020.12.031_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1084\/jem.20180752","article-title":"VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells","volume":"216","author":"Greenwald","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Canc. Sci."},{"key":"10.1016\/j.canlet.2020.12.031_bib29","series-title":"IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma","author":"Wu","year":"2020"},{"key":"10.1016\/j.canlet.2020.12.031_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.12.031_bib31","first-page":"3163","article-title":"Drug-related hypertension associated with the efficacy of apatinib on hepatocellular carcinoma","volume":"12","author":"Yang","year":"2020","journal-title":"Canc. Manag. Res."},{"issue":"62","key":"10.1016\/j.canlet.2020.12.031_bib32","doi-asserted-by":"crossref","first-page":"105596","DOI":"10.18632\/oncotarget.22337","article-title":"Apatinib is effective for treatment of advanced hepatocellular carcinoma.pdf>","volume":"8","author":"Kong Yl","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.12.031_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1006233521325","article-title":"Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper","volume":"55","author":"Small","year":"1999","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.canlet.2020.12.031_bib34","doi-asserted-by":"crossref","first-page":"107527","DOI":"10.1016\/j.pharmthera.2020.107527","article-title":"Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments","volume":"211","author":"Perini","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2020.12.031_bib35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.110.227454","article-title":"Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction","volume":"107","author":"Leuschner","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.canlet.2020.12.031_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.phrs.2011.11.005","article-title":"Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA\/2 mice","volume":"65","author":"Sarro","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2020.12.031_bib37","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib38","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-018-0563-y","article-title":"Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.12.031_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2017.07.037","article-title":"Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance","volume":"84","author":"Li","year":"2017","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.canlet.2020.12.031_bib41","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2020.12.031_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.canlet.2020.12.031_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI133250","article-title":"Not all proteinuria is created equal","volume":"130","author":"Beenken","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.12.031_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","article-title":"Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2020.12.031_bib45","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1158\/1078-0432.CCR-1183-3","article-title":"Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells","volume":"10","author":"Duxbury","year":"2004","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.12.031_bib46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejmech.2016.10.028","article-title":"Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein","volume":"124","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2020.12.031_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.2014010060","article-title":"Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney","volume":"26","author":"Dimke","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.canlet.2020.12.031_bib48","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling","volume":"21","author":"Sison","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.canlet.2020.12.031_bib49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.canlet.2020.12.031_bib50","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.12.031_bib51","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cmet.2017.01.004","article-title":"Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease","volume":"25","author":"Falkevall","year":"2017","journal-title":"Cell Metabol."},{"key":"10.1016\/j.canlet.2020.12.031_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/molmed.2010.00111","article-title":"Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition","volume":"17","author":"Liu","year":"2011","journal-title":"Mol Med"},{"key":"10.1016\/j.canlet.2020.12.031_bib53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","author":"Collaboration","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.canlet.2020.12.031_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030747","article-title":"Association between angiotensin-converting enzyme inhibitors and lung cancer-A nationwide, population-based, propensity score-matched cohort study","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2020.12.031_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2017.09.007","article-title":"Captopril improves tumor nanomedicine delivery by increasing tumor blood perfusion and enlarging endothelial gaps in tumor blood vessels","volume":"410","author":"Zhang","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.12.031_bib56","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.12.031_bib57","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Sch\u00f6del","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.canlet.2020.12.031_bib58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/onc.2011.366","article-title":"Erythropoietin receptor contributes to melanoma cell survival in vivo","volume":"31","author":"Kumar","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.12.031_bib59","series-title":"Erythropoietin Regulation by Angiotensin II","author":"Kim","year":"2017"},{"key":"10.1016\/j.canlet.2020.12.031_bib60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.exphem.2010.12.002","article-title":"Captopril modulates hypoxia-inducible factors and erythropoietin responses in a murine model of total body irradiation","volume":"39","author":"Barshishat-Kupper","year":"2011","journal-title":"Exp. Hematol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520307023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520307023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:55:58Z","timestamp":1759593358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520307023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":60,"alternative-id":["S0304383520307023"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.12.031","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-72739\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-72739\/v2","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}